MAKO data validates knee, hip applications, says Piper Jaffray

theflyonthewall.com

Piper Jaffray says clinical data presented this week validates the benefits of MAKO Surgical's knee and hip applications and implants. Piper reiterates an Overweight rating on the stock with a $23 price target.

Rates

View Comments (1)